Ropes & Gray represented CAMP4 Therapeutics in the transaction, and Paul Hastings represented the underwriters. CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company, announced...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Zenas BioPharma in the transaction, and Cooley represented the underwriters. Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company, announced...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Bicara Therapeutics on the offering, and Ropes & Gray advised the underwriters. Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company, announced the...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented LianBio on the deal. LianBio (Nasdaq: LIAN) announced it has entered into an agreement with Bristol Myers Squibb (NYSE:BMY)(BMS), whereby BMS has obtained...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Verastem, while Covington advised the underwriters in the offering. Verastem, Inc. announced its $85 million public offering of common stock and pre-funded warrants....
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Provention Bio, Inc. on the deal. Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced a sales agreement...
You must be a Standard 1 Year member to access this content.
Zhong Lun and Ropes & Gray advised LianBio on the deal. LianBio executed an initial public offering and listing of American depositary shares on the Nasdaq...
You must be a Standard 1 Year member to access this content.
